A Phase I, Randomized, Double-Blind Crossover Pharmacokinetic, Pharmacodynamic, and Safety Study of Subcutaneously Administered Humalog® (Insulin Lispro Injection; Rapid-Acting Insulin) With and Without Recombinant Human Hyaluronidase (rHuPH20) Versus Subcutaneously Administered Humulin R® (Regular Insulin Injection) With and Without rHuPH20

Trial Profile

A Phase I, Randomized, Double-Blind Crossover Pharmacokinetic, Pharmacodynamic, and Safety Study of Subcutaneously Administered Humalog® (Insulin Lispro Injection; Rapid-Acting Insulin) With and Without Recombinant Human Hyaluronidase (rHuPH20) Versus Subcutaneously Administered Humulin R® (Regular Insulin Injection) With and Without rHuPH20

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Sep 2014

At a glance

  • Drugs Insulin (Primary) ; Hyaluronidase; Insulin lispro
  • Indications Diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors Halozyme Therapeutics
  • Most Recent Events

    • 29 Sep 2009 Results have been presented at the 69th Annual Scientific Sessions of the American Diabetes Association and will be presented at the 45th Annual Meeting of the European Association for the Study of Diabetes, according to a Halozyme media release.
    • 29 May 2009 Results published in the Journal of Diabetes Technology and Therapeutics, according to a Halozyme media release.
    • 16 Jul 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top